Granted Patent
B2
US 12,209,138 · App. 17/823,905 · Granted Jan 28, 2025
Anti-CD38 antibodies
Inventors:
Kathleen Ann Elias (South San Francisco, CA); Gregory Landes (San Bruno, CA); Shweta Singh (South San Francisco, CA); Wouter Korver (South San Francisco, CA); Andrew Walling Drake (South San Francisco, CA); Mary Haak-Frendscho (San Francisco, CA); Gyorgy Pal Snell (South San Francisco, CA); Vinay Bhaskar (South San Francisco, CA)
Assignee:
Takeda Pharmaceutical Company Limited
C07K16/40A61K47/6871C07K16/2896C12N9/99A61K2039/505C07K2317/24C07K2317/30C07K2317/33C07K2317/34C07K2317/52C07K2317/56C07K2317/565C07K2317/732C07K2317/734C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
Claims (26)
1. A method of treating an autoimmune disease comprising administering to a patient in need thereof an isolated antibody that specifically binds human CD38 as set forth in SEQ ID NO:1 and cynomolgus CD38 as set forth in SEQ ID NO:2, wherein the isolated antibody comprises:
a) a heavy chain variable region comprising:
i) a first CDR comprising SEQ ID NO:3;
ii) a second CDR comprising SEQ ID NO:4; and
iii) a third CDR comprising SEQ ID NO:5; and
b) a light chain variable region comprising:
i) a first CDR comprising SEQ ID NO:6;
ii) a second CDR comprising an RDS amino acid sequence; and
iii) a third CDR comprising SEQ ID NO:8,
wherein the heavy chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:9 and the light chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:10.
2. The method according to claim 1 , wherein the autoimmune disease is selected from the group consisting of myasthenia gravis, immune thrombocytopenia purpura, and ulcerative colitis.
3. The method according to claim 1 , wherein the autoimmune disease is myasthenia gravis.
4. The method according to claim 1 , wherein the autoimmune disease is immune thrombocytopenic purpura.
5. The method according to claim 1 , wherein the autoimmune disease is ulcerative colitis.
6. The method according to claim 1 , wherein the heavy chain variable region comprises an amino acid sequence having an identity of at least 95% to SEQ ID NO:9 and the light chain variable region comprises an amino acid sequence having an identity of at least 95% to SEQ ID NO:10.
7. The method according to claim 1 , wherein the heavy chain variable region comprises an amino acid sequence having an identity of at least 99% to SEQ ID NO:9 and the light chain variable region comprises an amino acid sequence having an identity of at least 99% to SEQ ID NO:10.
8. The method according to claim 1 , wherein the isolated antibody interacts with at least K121, F135, Q139, D141, E239, W241, C275, K267, F284, P291, and E292 of SEQ ID NO: 1 and SEQ ID NO:2, wherein the numbering is based on SEQ ID NO:1.
9. The method according to claim 1 , wherein the isolated antibody binds to human CD38 (SEQ ID NO: 1) with a KD of at least 10 −8 M, and wherein the affinity is measured by surface plasmon resonance (SPR) analysis.
10. The method according to claim 1 , wherein the isolated antibody further comprises an Fc domain.
11. The method according to claim 10 , wherein the Fc domain is a human Fc domain.
12. The method according to claim 11 , wherein the Fc domain is a variant Fc domain.
13. The method according to claim 10 , wherein the isolated antibody is a human IgG antibody.
14. The method according to claim 13 , wherein the isolated antibody is a human IgG1 antibody.
15. The method according to claim 1 , wherein administering the isolated antibody depletes activated cells expressing CD38 protein (SEQ ID NO: 1).
16. The method according to claim 1 , wherein administering the isolated antibody inhibits growth of a cell expressing a human CD38 protein (SEQ ID NO: 1).
17. The method according to claim 1 , wherein administering the isolated antibody inhibits biological activity of a human CD38 protein (SEQ ID NO: 1).
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2022
From: BHASKAR, VINAY
To: XOMA (US) LLC
Reel/Frame 061307/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2022
From: XOMA (US) LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061307/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2022
From: ELIAS, KATHLEEN ANN; LANDES, GREGORY; SINGH, SHWETA; KORVER, WOUTER; DRAKE, ANDREW WALLING; HAAK-FRENDSCHO, MARY; SNELL, GYORGY PAL
To: TAKEDA CALIFORNIA, INC.
Reel/Frame 061307/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2022
From: TAKEDA CALIFORNIA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061307/0816 →
Continuity (10)
Provisional Application
61428699
· Dec 30, 2010
Provisional Application
61470382
· Mar 31, 2011
Provisional Application
61470406
· Mar 31, 2011
Provisional Application
61485104
· May 11, 2011
References Cited (240)
US 6086875A
· Blumberg et al.
· 2000
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7317091B2
· Lazar et al.
· 2008
[cited by applicant]
US 7670600B2
· Dall'Acqua et al.
· 2010
[cited by applicant]
US 7829673B2
· De Weers et al.
· 2010
[cited by applicant]
US 8084582B2
· Dahiyat et al.
· 2011
[cited by applicant]
US 8088896B2
· Tesar et al.
· 2012
[cited by applicant]
US 8188231B2
· Lazar et al.
· 2012
[cited by applicant]
US 8362211B2
· Elias et al.
· 2013
[cited by applicant]
US 8367805B2
· Chamberlain et al.
· 2013
[cited by applicant]
US 8877899B2
· Rojkjaer et al.
· 2014
[cited by applicant]
US 8926969B2
· Elias
· 2015
[cited by examiner]
US 8937158B2
· Lazar et al.
· 2015
[cited by applicant]
US 9040041B2
· Desjarlais et al.
· 2015
[cited by applicant]
US 9040050B2
· van de Winkel et al.
· 2015
[cited by applicant]
US 9102744B2
· Elias et al.
· 2015
[cited by applicant]
US 9289490B2
· Rojkjaer et al.
· 2016
[cited by applicant]
US 9676869B2
· Elias et al.
· 2017
[cited by applicant]
US 9790285B2
· Elias
· 2017
[cited by applicant]
US 9944711B2
· De Weers et al.
· 2018
[cited by applicant]
US 20060235208A1
· Lazar et al.
· 2006
[cited by applicant]
US 20070003554A1
· Miller
· 2007
[cited by applicant]
US 20070148170A1
· Desjarlais et al.
· 2007
[cited by applicant]
US 20090076249A1
· De Weers et al.
· 2009
[cited by applicant]
US 20090203538A1
· Sugioka et al.
· 2009
[cited by applicant]
US 20110262454A1
· Park et al.
· 2011
[cited by applicant]
US 20140154247A1
· Behrens et al.
· 2014
[cited by applicant]
US 20150231235A1
· van de Winkel et al.
· 2015
[cited by applicant]
US 20160067205A1
· Lokhorst et al.
· 2016
[cited by applicant]
US 20160075766A1
· Ritter et al.
· 2016
[cited by applicant]
US 20160130362A1
· De Weers et al.
· 2016
[cited by applicant]
US 20160168266A1
· Yamazaki et al.
· 2016
[cited by applicant]
US 20170121417A1
· Jansson et al.
· 2017
[cited by applicant]
US 20180117150A1
· O'Dwyer et al.
· 2018
[cited by applicant]
US 20180235986A1
· Labotka et al.
· 2018
[cited by applicant]
CN 103282383A
· 2013
[cited by applicant]
CN 107365385A
· 2017
[cited by applicant]
EP 1914242
· 2008
[cited by applicant]
EP 2658871B1
· 2018
[cited by applicant]
JP 2001509817A
· 2001
[cited by applicant]
JP 2014502491A
· 2014
[cited by applicant]
JP 2014509837A
· 2014
[cited by applicant]
JP 2014514345A
· 2014
[cited by applicant]
JP 2015511008A
· 2015
[cited by applicant]
JP 2015522822A
· 2015
[cited by applicant]
JP 2016536314A
· 2016
[cited by applicant]
KR 1020140032963A
· 2014
[cited by applicant]
TW 201919699A
· 2019
[cited by applicant]
WO WO1994013804A1
· 1994
[cited by applicant]
WO WO9845331
· 1998
[cited by applicant]
WO WO2003011161A1
· 2003
[cited by applicant]
WO WO2006099875
· 2006
[cited by applicant]
WO WO2006125640
· 2006
[cited by applicant]
WO WO2008037257
· 2008
[cited by applicant]
WO WO2008047242A2
· 2008
[cited by applicant]
WO WO2009077993
· 2009
[cited by applicant]
WO WO2010021874
· 2010
[cited by applicant]
WO WO2010061357A1
· 2010
[cited by applicant]
WO WO2010061358A1
· 2010
[cited by applicant]
WO WO2010061359A1
· 2010
[cited by applicant]
WO WO2010061360A1
· 2010
[cited by applicant]
WO WO2012076663A1
· 2012
[cited by applicant]
WO WO2012080721A1
· 2012
[cited by applicant]
WO WO2012092612
· 2012
[cited by applicant]
WO WO2012092616
· 2012
[cited by applicant]
WO WO2012118750A2
· 2012
[cited by applicant]
WO WO2012151199A1
· 2012
[cited by applicant]
WO WO2013132245A1
· 2013
[cited by applicant]
WO WO2014089416A1
· 2014
[cited by applicant]
WO WO2015066450A1
· 2015
[cited by applicant]
WO WO2016180958A1
· 2016
[cited by applicant]
WO WO2017079150A1
· 2017
[cited by applicant]
WO WO2018013917A1
· 2018
[cited by applicant]
WO WO2019089832A1
· 2019
[cited by applicant]
Aggarwal, Rohit et al. “Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.” Arthritis care & research vol. 63,6 (2011): 891-8. doi:10.1002/acr.20446.
[cited by applicant]
Alexander, Tobias et al. “The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.” Annals of the rheumatic diseases vol. 74,7 (2015)…
[cited by applicant]
Alvarez-Rodriguez, Lorena et al. “Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome.” International journal of molecular sciences vol. 19,2 589. Feb. 16, 2018.
[cited by applicant]
Antonelli, A et al. “Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease.” Clinical and experimental immunology vol. 126,3 (2001): 426-31.
[cited by applicant]
Antonelli, A, and E Ferrannini. “CD38 autoimmunity: recent advances and relevance to human diabetes.” Journal of endocrinological investigation vol. 27,7 (2004): 695-707.
[cited by applicant]
Atanackovic, Djordje et al. “Immunotherapies targeting CD38 in Multiple Myeloma.” Oncoimmunology vol. 5,11 e1217374. Aug. 5, 2016, doi:10.1080/2162402X.2016.1217374.
[cited by applicant]
Banchereau, Romain et al. “Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.” Cell vol. 165,3 (2016): 551-65.
[cited by applicant]
Barbas, C F 3rd et al. “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.” Proceedings of the National Academy of Science…
[cited by applicant]
Behzad, Masumeh Maleki et al. “Cellular expression of CD markers in immune thrombocytopenia purpura: implications for prognosis.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica vol. 126,6 (2018):…
[cited by applicant]
Bird, R E et al. “Single-chain antigen-binding proteins.” Science (New York, N.Y.) vol. 242,4877 (1988): 423-6.
[cited by applicant]
Casneuf, Tineke et al. “Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.” Blood advances vol. 1,23 2105-2114. Oct. 24, 2017.
[cited by applicant]
Chiba, Asako et al. “The involvement of V(alpha) 14 natural killer T cells in the pathogenesis of arthritis in murine models.” Arthritis and rheumatism vol. 52,6 (2005): 1941-8.
[cited by applicant]
Chihara, Norio et al. “Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.” Proceedings of the National Academy of Sciences of the United States of Americ…
[cited by applicant]
Chothia, C, and A M Lesk. “Canonical structures for the hypervariable regions of immunoglobulins.” Journal of molecular biology vol. 196,4 (1987): 901-17.
[cited by applicant]
Clemens, Pamela L et al. “Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.” Clinical pharmac…
[cited by applicant]
Cohen, Adam D, and Raymond L Comenzo. “Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.” Hematology. American Society of Hematology. Education Program vol. 2010 (2010): 287-94.
[cited by applicant]
Cole, Suzanne et al. “Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.” Arthritis research & therapy vol. …
[cited by applicant]
Cooper, L J et al. “Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains.” Journal of immunology…
[cited by applicant]
Costello, Caitlin. “An update on the role of daratumumab in the treatment of multiple myeloma.” Therapeutic advances in hematology vol. 8,1 (2017): 28-37.
[cited by applicant]
Daratumumab (Darzalex) I FDA, May 17, 2017, retrieved from the Internet: URL:https://www.fda.gov/drugs/resources-information-approved-drugs/daratumumab-darzalex.
[cited by applicant]
Dimopoulos et al. (2018) Blood 132 (suppl. 1): ASH abstract 155/ oral presentation.
[cited by applicant]
Draborg, A.H., Lydolph MC, Westergaard M, et al., PLoS One (2015) 10(9):e0138753. doi: 10.1371/journal.pone.0138753. eCollection 2015.
[cited by applicant]
Dürig, J et al. “CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.” Leukemia vol. 16,1 (2002): 30-5.
[cited by applicant]
Edwards, Bryan M et al. “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS.” Journal of molecular biology vol. 334,1 (2003): 103-1…
[cited by applicant]
Fassbinder, T., Saunders U, Mickholz E, et al., Arthritis Res Ther (2015).
[cited by applicant]
Fedyk, E et al. “A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics.” Blood 2018; 132 (Supplement 1): 3249. doi: https://doi.org/10.11…
[cited by applicant]
Friberg, Lena E et al. “Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 20,24 (2…
[cited by applicant]
Gertz, Morie A et al. “Amyloidosis and Waldenstrom's macroglobulinemia.” Hematology. American Society of Hematology. Education Program (2004): 257-82.
[cited by applicant]
Gibiansky, Leonid, and Ekaterina Gibiansky. “Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of bio…
[cited by applicant]
Glassman, Patrick M, and Joseph P Balthasar. “Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.” Cancer biology & medicine vol. 11,1 (2014): 20-33.
[cited by applicant]
Grammer, Amrie C et al. “Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.” The Journal of clinical investigation vol. 112,10 (2003): 1506-20.
[cited by applicant]
Hamblin, Terry J et al. “CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.”…
[cited by applicant]
Han, Chao, and Honghui Zhou. “Monoclonal antibodies: interspecies scaling with minimal preclinical information.” Therapeutic delivery vol. 2,3 (2011): 359-68.
[cited by applicant]
Hawkins, R E et al. “Selection of phage antibodies by binding affinity. Mimicking affinity maturation.” Journal of molecular biology vol. 226,3 (1992): 889-96.
[cited by applicant]
Holliger, P et al. “Diabodies”: small bivalent and bispecific antibody fragments. Proceedings of the National Academy of Sciences of the United States of America vol. 90,14 (1993): 6444-8.
[cited by applicant]
Huston, J S et al. “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Hutchinson, A., “Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts” Human Immunology, vol. 75, Issue 9 (2014) pp. 986-990.
[cited by applicant]
International Myeloma Working Group. “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.” British journal of haematol…
[cited by applicant]
IOTest&αχιρχ; CD38-PE // A07779CE_C Feb. 6, 2006 //[online], [found on Nov. 3, 2020]. found on: https://www.bc-cytometry.com/PDF/DataSheet/A07779_D.S.pdf.
[cited by applicant]
Ishizawa, Kenichi et al. “Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.” Japanese jour…
[cited by applicant]
Jackson, J R et al. “In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta.” Journal of immunology (Baltimore, Md. : 1950) vol. 154,7 (1995): 3310-9.
[cited by applicant]
Jackson, N et al. “An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.” Clinical and experimental immunology vol. 72,3 (…
[cited by applicant]
Jelinek, D F et al. “Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.” British journal of haematology vol. 115,4 (200…
[cited by applicant]
Kabat et al. (1991) Sequences Of Proteins Of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD.
[cited by applicant]
Kamath, Amrita V. “Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.” Drug discovery today. Technologies vol. 21-22 (2016): 75-83.
[cited by applicant]
Kato, Atsuhiko et al. “Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model.” Experimental and molecular pathology vol. 84,3 (2008): 262-70.
[cited by applicant]
Keizer, R J et al. “Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.” CPT: pharmacometrics & systems pharmacology vol. 2,6 e50. Jun. 26, 2013.
[cited by applicant]
Keyhani, A et al. “Increased CD38 expression is associated with favorable prognosis in adult acute leukemia.” Leukemia research vol. 24,2 (2000): 153-9.
[cited by applicant]
Kormelink, T. G. et al. “Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.” Annals of the rheumatic dis…
[cited by applicant]
Kosmas, C et al. “Anti-CD20-based therapy of B cell lymphoma: state of the art.” Leukemia vol. 16,10 (2002): 2004-15.
[cited by applicant]
Kraan, M C et al. “Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis.” Rheumatology (Oxford, England) vol. 38, 11 (1999): 1074-80.
[cited by applicant]
Krejcik, Jakub et al. “Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.” Blood vol. 128,3 (2016): 384-94.
[cited by applicant]
Kyle, Robert A et al. “Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.” The New England journal of medicine vol. 356,25 (2007): 2582-90.
[cited by applicant]
Laubach, Jacob P, and Paul G Richardson. “CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.” Clinical cancer research : an official journal of the American Association for Cancer Research v…
[cited by applicant]
Lloyd, C et al. “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens.” Protein engineering, design & selection : PEDS vol. 22,3…
[cited by applicant]
Lugar, Patricia L et al. “Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus.” PloS one vol. 7,9 (2012): e44362. doi:10.1371/journal.pone.0044362.
[cited by applicant]
Mager, Donald E et al. “Diversity of mechanism-based pharmacodynamic models.” Drug metabolism and disposition: the biological fate of chemicals vol. 31,5 (2003): 510-8.
[cited by applicant]
Malavasi, F., Deaglio S, Funaro A, et al., Physiol Rev (2008) 88(3):841-86.
[cited by applicant]
Mallone, R et al. “Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization.” Diabetes vol. 50,4 (2001): 752-62.
[cited by applicant]
Marinov, J et al. “Immunophenotypic significance of the “lymphoid” CD38 antigen in myeloid blood malignancies.” Neoplasma vol. 40,6 (1993): 355-8.
[cited by applicant]
Marks, J., Griffiths, A., Malmqvist, M et al. By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling. Nat Biotechnol 10, 779-783 (1992).
[cited by applicant]
Martin, W. et al., “Serum-free light chain—a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia”, Translational Research, vol. 149, Issue 4, 2007, pp. 231-235, https://doi.org/1…
[cited by applicant]
Mei, H. et al. “Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.” Arthritis research & therapy vol. 14 Suppl 5,Suppl 5 (2012): S1. doi: 10.1186/ar3909.
[cited by applicant]
Merlini, Giampaolo, and Vittorio Bellotti. “Molecular mechanisms of amyloidosis.” The New England journal of medicine vol. 349,6 (2003): 583-96.
[cited by applicant]
Mihara, M et al. “Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.” Clinical immunology (Orlando, Fla.) vol. 98,3 (2001): 319-26.
[cited by applicant]
Morabito, F et al. “Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia.” Leukemia research vol. 25,11 (2001): 927-32.
[cited by applicant]
Murray et al. (2010) Blood (ASH Annual Meeting Abstracts) 116 (21): abstr 1909.
[cited by applicant]
Mustafa, Nurulhuda et al., “Daratumumab Efficiently Targets NK/T Cell Lymphoma with High CD38 Expression.” Blood 2017; 130 (Supplement 1): 2814.
[cited by applicant]
Nijhof, Inger S et al. “CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.” Blood vol. 128,7 (2016): 959-70.
[cited by applicant]
Nilsson and Koke (2001) Drug Inform. J. 35: 1289-1299.
[cited by applicant]
Palumbo, Antonio et al. “International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation…
[cited by applicant]
Pinto, L. et al. “Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.” Cytometry. Part B, Clinical cytometry vo…
[cited by applicant]
Raab, M. S. et al. “Phase I/lla Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma.” Blood, vol. 126,23, 2015, p. 3035.
[cited by applicant]
Rajkumar, S Vincent et al. “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.” Blood vol. 117,18 (2011): 4691-5. doi:10.1182/blood-20…
[cited by applicant]
Reiter, Y et al. “Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.” Nature biotechnology vol. 14,10 (1996): 1239-45.
[cited by applicant]
Richter et al. (2016) J. Clin. Oncol. 34 (suppl): abstr 8005.
[cited by applicant]
Roepcke, Stefan et al. “Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey—model assisted preparation for the first in human trial.” Pharmacology research & pers…
[cited by applicant]
Schier, R et al. “Identification of functional and structural amino-acid residues by parsimonious mutagenesis.” Gene vol. 169,2 (1996): 147-55.
[cited by applicant]
Smithson, G. et al. “TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion.” J. Immunol. 198 (1 Supplement) (2017) 224.20.
[cited by applicant]
Sonneveld, Pieter, and Annemiek Broijl. “Treatment of relapsed and refractory multiple myeloma.” Haematologica vol. 101,4 (2016): 396-406.
[cited by applicant]
Stebbings, Richard et al. ““Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.” Journal of immunology (Baltimore, M…
[cited by applicant]
Study NCT02219256. A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants, clinicaltrials.gov, Mar. 22, 2017, pp. 1-13; found on the Internet Dec. 15, 2021, URL: http…
[cited by applicant]
Sullivan, Harold C et al. “Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.” Blood vol. 129,22 (2017): 3033-3037.
[cited by applicant]
Tomlinson, I, and P Holliger. “Methods for generating multivalent and bispecific antibody fragments.” Methods in enzymology vol. 326 (2000): 461-79.
[cited by applicant]
Uchiyama, Yasushi et al. “Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha.” Rheumatology international vol. 28,9 (2008): 879-83.
[cited by applicant]
Uchiyama, Yasushi et al. “Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.” Biological & pharmaceutical bulletin vol. 31,6 (2008…
[cited by applicant]
Usmani S.Z. et al., Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients(pts) with Relapsed or Refractory Multiple Myeloma (PAVO), Blood, 2016, vol. 128 …
[cited by applicant]
Van Bueren, J. et al. “Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79” Blood 2014; 124 (21): 3474. doi: https://doi.org/10.1182/blood.V124.21.3474.3474.
[cited by applicant]
Van de Donk, Niels W C J et al. “CD38 antibodies in multiple myeloma: back to the future.” Blood vol. 131,1 (2018): 13-29. doi: 10.1182/blood-2017-06-740944.
[cited by applicant]
Van de Donk, Niels W C J et al. “Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.” Immunological reviews vol. 270,1 (2016): 95-112.
[cited by applicant]
Vital, Edward M et al. “B cell biomarkers of rituximab responses in systemic lupus erythematosus.” Arthritis and rheumatism vol. 63, 10 (2011): 3038-47.
[cited by applicant]
Voorhees, Peter M., et al. “Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002” (Sir…
[cited by applicant]
Walpole, Sarah Catherine et al. “The weight of nations: an estimation of adult human biomass.” BMC public health vol. 12 439. Jun. 18, 2012, doi:10.1186/1471-2458-12-439.
[cited by applicant]
Wang et al. (2016) Arthritis Rheumatol. 68(suppl 10). 2016 ACR/ARHP Annual Meeting, 1085.
[cited by applicant]
Ward, E S et al. “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Witzig, T E et al. “Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma.” Cancer vol. 72,1 (1993): 108-13.
[cited by applicant]
Xu, X S et al. “Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.” Clinical pharmacology and therapeutics vol. 101,6 (2017): 721-724.
[cited by applicant]
Yelton, D E et al. “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.” Journal of immunology (Baltimore, Md. : 1950) vol. 155,4 (1995): 1994-2004.
[cited by applicant]
Yilmaz, Vuslat et al. “Regulatory B cells in myasthenia gravis are differentially affected by therapies.” Annals of clinical and translational neurology vol. 5,11 1408-1414. Sep. 22, 2018.
[cited by applicant]
Yoshiga, Y et al. “Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis.” International journal of molecular medici…
[cited by applicant]
Yu. B. Belousov, K. G. Gurevich. Clinical pharmacokinetics. The practice of dosing drugs. Moscow, Litterra Publishing House, 2005, 288 p., see p. 18, last paragraph,—p. 20 (Russian).
[cited by applicant]
Zhang, Tiantian et al. “Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.” Oncotarget vol. 8,20 (2017): 34001-34017. doi…
[cited by applicant]
Study NCT02219256. A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants, clinicaltrials.gov, Sep. 22, 2017, pp. 1-13; found on the Internet Dec. 15, 2021, URL: http…
[cited by applicant]
U.S. Appl. No. 16/656,401, filed Oct. 17, 2019 (now allowed), under 35 U.S.C. § 120.
[cited by applicant]
U.S. Appl. No. 15/703,833, filed Sep. 17, 2017 (now issued as U.S. Pat. No. 10,494,444), under 35 U.S.C. § 120.
[cited by applicant]
U.S. Appl. No. 14/550,796, filed Nov. 21, 2014 (now issued as U.S. Pat. No. 9,790,285), under 35 U.S.C § 120.
[cited by applicant]
U.S. Appl. No. 13/720,837, filed Dec. 19, 2012 (now issued as U.S. Pat. No. 8,926,969), under 35 U.S.C § 120.
[cited by applicant]
U.S. Appl. No. 13/341,860, filed Dec. 30, 2011 (now issued as U.S. Pat. No. 8,362,211), under 35 U.S.C § 120.
[cited by applicant]
Duebel “Handbook of Therapeutic Antibodies Chapter 6” Handbook of Therapeutic Antibodies, pp. 119-144 (2007).
[cited by applicant]
Kiyoshi MA, et al: “Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition states stabilized the antibody-antigen complex”. PLo…
[cited by applicant]
Rich RL et al: “A global benchmark study using affinity-based biosensors” Analytical Biochemistry, Mar. 15, 2009;386(2): 194-216.
[cited by applicant]
Groen, Richard W. et al., “In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab in the Treatment of Multiple Myeloma”, Blood, vol. 116, No. 21, Nov. 2010, pp. 1261-1262, XP009157537.
[cited by applicant]
Kong, Sun-Young et al., “Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs”, Blood, vol. 116, No. 21, Nov. 2010, pp. 1241-1242, XP0091…
[cited by applicant]
Little, M. et al., “Of mice and men: hybridoma and recombinant antibodies”, Immunology Today, El Sevier Publications, Cambridge, GB, vol. 21, No. 8, Aug. 2000, pp. 364-370, XP004215163.
[cited by applicant]
Park, Peter U. et al., “SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies.”, Blood, vol. 112, No. 11, Nov. 2008, p. 951, XP009157535.
[cited by applicant]
De Weers et. al., “Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors”, J Immunology, 2010, 186(3): 1840-1848.
[cited by applicant]
Ellis et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma”, J Immunology, 1995, 155: 925-9237.
[cited by applicant]
Goldmacher et al., “Anti-CD38-blocked-ricin; An immunotoxin for the treatment of multiple myeloma”, Blood 84(9); 3017-25, Nov. 1, 1994.
[cited by applicant]
Stevenson et al., “Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody”, Blood, 1991, 77: 1071-1079.
[cited by applicant]
Van Noort et al., Cell biology of autoimmune diseases.,
[cited by applicant]
Kuerten et al., MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.,
[cited by applicant]
Ferrero et al., Characterization and phylogenetic epitope mapping of CD38 Adpr cyclase in the cynomolgus macaque.,
[cited by applicant]
Ausiello et al., Functional topography of discrete domains of human CD38.,
[cited by applicant]
Odendahl M., “Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.”,
[cited by applicant]
Odendahl.M., “Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus.”,
[cited by applicant]
Owczarczyk K., “A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.”,
[cited by applicant]
Pavón E.J., “Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells.”,
[cited by applicant]
Vital E.M., “Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.”,
[cited by applicant]
Foote, J., et al. “Antibody framework residues affecting the conformation of the hypervariable loops.”
[cited by applicant]
Winter, G., et al. “Humanized antibodies.” Immunology today, vol. 14,6 (1993): 243-6.
[cited by applicant]
U.S. Appl. No. 16/656,401, filed Oct. 17, 2019, now U.S. Pat. No. 11,434,304.
[cited by applicant]
U.S. Appl. No. 17/823,905, filed Aug. 31, 2022.
[cited by applicant]
U.S. Appl. No. 13/977,207, filed Feb. 13, 2014, now U.S. Pat. No. 9,102,744.
[cited by applicant]
U.S. Appl. No. 14/754,592, filed Jun. 29, 2015, now U.S. Pat. No. 9,676,869.
[cited by applicant]
U.S. Appl. No. 15/598,241, filed May 17, 2017, now U.S. Pat. No. 10,336,833.
[cited by applicant]
U.S. Appl. No. 16/412,297, filed May 14, 2019.
[cited by applicant]
U.S. Appl. No. 16/961,346, filed Jul. 10, 2020.
[cited by applicant]
U.S. Appl. No. 17/041,783, filed Sep. 25, 2020.
[cited by applicant]
U.S. Appl. No. 17/617,811, filed Jan. 23, 2020.
[cited by applicant]
U.S. Appl. No. 16/317,606, filed Dec. 9, 2021, now U.S. Pat. No. 11,613,586.
[cited by applicant]
U.S. Appl. No. 18/169,767, filed Jan. 14, 2019.
[cited by applicant]
Shaul, Merav E et al. “Tumor-associated neutrophils display a distinct N1 profile Following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs.” Oncoimmunology vol. 5,11 e1232221. Sep. 13, 2016, doi:…
[cited by applicant]
Stevenson, G. T., “CD38 as a Therapeutic Target”, Molecular Medicine, 2006, vol. 12, pp. 345-346.
[cited by applicant]